NEW YORK, Dec. 12 — MDS Pharma Services and Iconix Pharmaceuticals announced Wednesday an agreement to develop a new system to evaluate drug efficacy and toxicity. The system, called DrugMatrix, will combine chemical, genomic, and pharmacological information to allow for rapid profiling of drug candidates. Incyte, which entered an agreement with and made an equity investment in Iconix in May 2001, will commercialize the new platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.